Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02174549Phase 1Recruiting

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Role: lead

NCT03259867Phase 2Recruiting

Combination of TATE and PD-1 Inhibitor in Liver Cancer

Role: lead

NCT04701476Phase 2Recruiting

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Role: lead

NCT03145558Phase 2Terminated

TATE Versus TACE in Intermediate Stage HCC

Role: lead

All 4 trials loaded